Jim Cramer's top 10 things to watch in the stock market Monday
Jim Cramer’s Monday watchlist cites stock-futures strength led by Nasdaq semiconductors, plus Middle East and WTI crude steadiness. It highlights Bristol Myers Squibb buying Nvidia AI hardware for drug R&D, Barclays raising Astera Labs target to $325, UBS covering Honeywell Aerospace at $231 hold, and analyst target changes for Accenture, Yeti, PNC, and Citi.
How this was made
The 30-second read
Why it matters
The only clearly actionable, company-specific trading catalysts are the analyst upgrades and price target changes (Astera Labs, Yeti, PNC) plus the scheduled Starship test timing. Other mentions (partnerships, BMS buying Nvidia hardware, Honeywell aftermarket rollout) are supportive but lack quantified financial impact.
Market read
This is primarily a daily watchlist, so it offers limited new decision-making beyond near-term sell-side catalyst reactions and event timing into the Starship test.
What to watch
The article is a multi-name watchlist, so liquidity and index flows (especially Nasdaq) may dominate single-stock reactions more than the cited fundamentals.
Background
Jim Cramer’s Monday watchlist summarizes futures action and highlights several company-specific items including analyst price target changes, an AI compute purchase by BMS, and a scheduled SpaceX Starship test.
Ticker impact
Bristol Myers Squibb is buying Nvidia’s newest enterprise AI computing system for drug discovery, citing R&D process changes from older hardware.
Mild positive bias, likely more sentiment than immediate earnings impact.
The article discloses a specific new system purchase by BMS, but provides no financial terms or volume, limiting magnitude.
Bristol Myers Squibb will use Nvidia’s newest enterprise AI computing system to expand drug discovery and development horsepower.
Limited immediate price impact; more medium-term strategic benefit.
The news is operational and strategic, with no disclosed spend, guidance, or clinical outcomes.
Barclays raised its price target on Astera Labs to $325 from $200 and kept a buy rating, citing Amazon-driven connectivity revenue potential.
Potential upside bias as traders react to the large target increase.
The article includes a specific PT change, rating, and a stated revenue thesis tied to Amazon spend.
Aeromexico will implement HONA’s anti-collision Surface Alerts across its Boeing planes, expanding Honeywell Aerospace aftermarket safety tech deployment.
Moderate positive bias, though magnitude depends on contract size not provided.
The article links a specific customer implementation to Honeywell’s aftermarket profit driver, but omits financial terms.
Wells Fargo cut its Accenture price target to $194 from $200 but kept a buy rating, citing updated earnings estimates after a $5 billion debt raise.
Likely limited net impact; traders may focus on the PT reduction.
The article provides both a PT cut and a rationale, but no new guidance from Accenture itself.
Goldman Sachs upgraded Yeti to buy from hold and raised its price target to $63 from $46, citing more durable growth outlook.
Upside bias into the next sessions as positioning adjusts to the upgrade.
The article includes a specific upgrade, PT increase, and channel-check rationale.
Citi raised its PNC Financial price target to $290 from $280 and kept a buy rating after PNC reported better-than-expected Q2 earnings and revenue.
Supportive bias, but likely incremental versus the already-reported earnings beat.
The article’s newest fact is the PT change, but it references results from last Wednesday, implying partial recap.
Market effects
Reinforces AI compute demand in pharma and connectivity infrastructure, plus continued aftermarket growth focus in aerospace safety tech.
US-focused catalysts (sell-side actions, US-listed equities) with indirect read-through to global semis via Nasdaq strength.
AI model trust and US-China data concerns are highlighted, potentially affecting cross-border enterprise AI adoption narratives.
Counterpoint
Several items are analyst target changes or partnership mentions without quantified contract values, so price moves may fade if broader macro risk rises.
Key entities
- companyBristol Myers Squibb
Buying Nvidia’s newest enterprise AI computing system for drug discovery and development.
- companyNvidia
Enterprise AI compute demand referenced via BMS purchase and pharma partnerships.
- companyAstera Labs
Barclays raised price target to $325 from $200 and kept buy rating.
- companyYeti
Goldman upgraded to buy from hold and raised price target to $63 from $46.
- companyPNC Financial Services
Citi raised price target to $290 from $280 and kept buy rating after Q2 beat.
